U.S. Breast Cancer Market Size, Share & Forecast 2026–2032

ID: MR-11267 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Breast Cancer Market
  • ✓Market Size 2024: USD 14.8 billion
  • ✓Market Size 2032: USD 24.4 billion
  • ✓CAGR: 6.6%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Biosimilar trastuzumab price erosion: Six trastuzumab biosimilars, including Kanjinti from Amgen and Trazimera from Pfizer, now compete with Genentech's Herceptin in U.S. hospital oncology. Biosimilar uptake has pushed average selling prices down sharply, shifting value toward HER2-directed antibody-drug conjugates such as Enhertu.
FINDING 02
Dense-breast supplemental imaging demand: Many investors treat U.S. breast imaging as saturated, but FDA's breast density notification rule, effective September 2024, forces disclosure to roughly 40 percent of screened women. That disclosure is driving demand for supplemental ultrasound, contrast-enhanced mammography, and MRI.
ANALYST RECOMMENDATION

Analyst Recommendation — Enter through diagnostics partnerships: Diagnostics entrants should secure distribution contracts with community oncology networks in 2025, targeting HER2-low and hormone receptor testing volumes. Filing for Medicare coverage now reduces payer friction and secures reimbursement codes before competitors.

Breast Cancer in the United States: Market Overview

The U.S. breast cancer market is among the most valuable oncology segments globally, anchored by roughly 310,000 new invasive cases projected for 2024 by the American Cancer Society. Unlike most global markets, spending is concentrated in branded targeted and endocrine therapies priced at premium levels, with Medicare Part D and commercial payers absorbing much of the cost. Medicare Part B covers screening mammography with no cost sharing, sustaining high diagnostic volume.

Market structure differs sharply from the global norm. The U.S. has higher per-patient oncology prices and faster adoption of new antibody-drug conjugates than Europe, with Enhertu from Daiichi Sankyo and AstraZeneca gaining rapid uptake after its 2019 approval. Hospital outpatient departments and independent oncology practices both act as dispensing points, creating a fragmented channel that rewards manufacturers with strong field reimbursement support. Medicare Part B reimburses infused agents at average sales price plus six percent.

Growth Drivers in the U.S. Breast Cancer Market

First, the U.S. Preventive Services Task Force's 2024 recommendation for biennial mammography starting at age 40 enlarges the screened population and the diagnosed pool. Second, CDK4/6 inhibitors including Ibrance from Pfizer, Kisqali from Novartis, and Verzenio from Eli Lilly have extended survival in HR-positive metastatic disease, expanding long-term treatment duration. Oncologists now sequence these agents earlier, with adjuvant CDK4/6 use confirmed by the NATALEE trial in 2024 for node-positive early disease.

Third, more than 4 million U.S. women have a history of breast cancer, sustaining recurrence surveillance and repeated biomarker testing. The FDA's August 2022 approval of Enhertu for HER2-low metastatic disease widened eligibility to roughly 55 percent of breast cancers, boosting demand for immunohistochemistry testing. Pathology laboratories must now score HER2 at the 1+ and 2+ levels with precision, which Medicare reimburses under the Clinical Laboratory Fee Schedule.

Market Restraints and Entry Barriers

Drug pricing is the dominant constraint. The Inflation Reduction Act of 2022 authorizes Medicare price negotiation, and Pfizer's Ibrance was selected in January 2025 for negotiated prices effective in 2027. Part B oncology agents, including most infused antibody-drug conjugates, face the same mechanism from 2028, compressing margins for late-line entrants. Entrants must model net price after mandatory rebates from Medicaid's best-price rule and commercial PBM rebates.

Biosimilar competition and payer utilization management add friction. Six trastuzumab biosimilars now compete with Herceptin, and PBMs such as CVS Caremark and Express Scripts use exclusive formularies and step therapy requirements that steer patients toward preferred biosimilars. Prior authorization delays in community oncology practices further slow new-launch uptake. Oral oncology drugs fall under Part D, where 340B contract pharmacy arrangements complicate channel economics for hospital-owned infusion sites.

Market Opportunities in U.S. Breast Cancer

The most concrete near-term opportunity sits in dense-breast supplemental imaging. Roughly 40 percent of screened women have dense tissue, and the FDA rule ensures each receives written notice. Contrast-enhanced mammography and abbreviated breast MRI vendors such as GE HealthCare and Hologic can target these patients through hospital imaging networks. Self-pay supplemental MRI typically costs several hundred dollars, creating a direct-to-consumer channel that bypasses prior authorization.

Second, HER2-low and HR-positive biomarker diagnostics represent a volume opportunity for laboratory developers. Community oncology practices adopting Enhertu must confirm HER2-low status with validated IHC assays, and companion diagnostic demand from Roche's PATHWAY HER2 assay illustrates how assay standardization drives pricing. Independent practices in Texas, Florida, and California, the three largest U.S. states by population, offer the densest volume for launch. Laboratories should target these three states first.

Regulatory and Policy Environment

The FDA regulates breast cancer therapeutics through its Oncology Center of Excellence and the Center for Devices and Radiological Health for imaging hardware and companion diagnostics under the Federal Food, Drug, and Cosmetic Act. The Mammography Quality Standards Act, administered by FDA, governs facility accreditation, and the 2024 density notification amendment imposes disclosure obligations effective September 10, 2024. Facilities must send written density notices alongside screening results.

Reimbursement sits with CMS, which sets Medicare Part B payment for infused agents and laboratory tests under the Clinical Laboratory Fee Schedule. Section 2713 of the Affordable Care Act requires private plans to cover screening mammography without cost sharing, while the CDC-funded National Breast and Cervical Cancer Early Detection Program serves uninsured women. Manufacturers must also comply with the Physician Payments Sunshine Act reporting for oncologist payments.

Long-Term Outlook for U.S. Breast Cancer Care

By 2032, U.S. spending is projected to reach roughly 24.4 billion dollars, growing at 6.6 percent annually, with volume gains from screening and survival extension driving most growth rather than price increases. Biosimilar penetration will moderate branded oncology spending, while ADCs and oral endocrine combinations expand share in metastatic and early-stage settings. Negotiated Medicare prices from the Inflation Reduction Act will reset net revenue for mature CDK4/6 franchises by 2027.

For entrants, the 2032 landscape rewards companies that combine diagnostic partnerships with patient navigation and value-based contracting. Expect consolidation among community oncology groups and growing payer scrutiny of drug waste, particularly for infused products administered in hospital outpatient settings. CMS's Enhancing Oncology Model, launched in 2023, will test value-based payment for breast cancer episodes through 2030. Entrants that document outcomes under the model will gain preferred positioning with payers.

Market at a Glance

MetricDetail
Market Size 2024USD 14.8 billion
Market Size 2032USD 24.4 billion
Growth Rate (CAGR)6.6%
Most Critical Decision FactorMedicare price negotiation exposure and net-of-rebate pricing
Largest RegionSouth Region
Competitive StructureOligopolistic, led by five branded oncology franchises

Leading Market Participants

  • Pfizer
  • AstraZeneca
  • Roche (Genentech)
  • Novartis
  • Eli Lilly
  • Merck
  • Daiichi Sankyo
  • Gilead Sciences
  • Hologic
  • Exact Sciences

Frequently Asked Questions

Secure FDA approval through a New Drug Application or Biologics License Application, then pursue listings on Medicare Part B or Part D formularies and major PBM templates. Parallel payer filings shorten the gap between approval and revenue.
Negotiated prices under the Inflation Reduction Act apply to drugs selected after several years on market, so launch models must assume future price reductions. Entrants should build net price assumptions that reflect negotiation exposure from the outset.
Biosimilars are viable for trastuzumab and bevacizumab-class products where FDA has already approved multiple competitors. Success depends on securing preferred PBM formulary placement and hospital contracting.
HER2-low and hormone receptor testing volumes are growing with new antibody-drug conjugate approvals. Laboratories with validated IHC assays and Medicare Clinical Laboratory Fee Schedule coverage hold the clearest path to revenue.
Texas, Florida, and California combine large patient populations with dense community oncology networks. Sequencing launches in these states builds payer evidence before national expansion.

Market Segmentation

By Treatment Type
  • Chemotherapy
  • Hormone Therapy
  • Targeted Therapy
  • Immunotherapy
  • Antibody-Drug Conjugates
By End User
  • Hospitals
  • Oncology Clinics
  • Ambulatory Surgical Centers
  • Diagnostic Imaging Centers
  • Academic Cancer Centers

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Breast Cancer Market - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Treatment Type Insights
4.1 Chemotherapy
4.2 Hormone Therapy
4.3 Targeted Therapy
4.4 Immunotherapy
4.5 Others
Chapter 05 End User Insights
5.1 Hospitals
5.2 Oncology Clinics
5.3 Ambulatory Surgical Centers
5.4 Diagnostic Imaging Centers
5.5 Others
Chapter 06 Competitive Landscape
6.1 Market Players
6.2 Leading Market Participants
6.2.1 Pfizer
6.2.2 AstraZeneca
6.2.3 Roche (Genentech)
6.2.4 Novartis
6.2.5 Eli Lilly
6.2.6 Merck
6.2.7 Daiichi Sankyo
6.2.8 Gilead Sciences
6.2.9 Hologic
6.2.10 Exact Sciences
6.3 Regulatory Environment
6.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.